BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 3, 2026
See today's BioWorld Asia
Home
» Biologics make some inroads, but generics still clog CFDA
To read the full story,
subscribe
or
sign in
.
Biologics make some inroads, but generics still clog CFDA
March 19, 2014
By
Shannon Ellis
SHANGHAI – The Center for Drug Evaluation (CDE) of the China Food and Drug Administration (CFDA) has released its annual report for 2013 which reveals only small gains have been made to fix the slow and overcrowded approval process.
BioWorld Asia